Pre-mRNA splicing and cancer: exon-mediated transcriptional amplification as an emerging hallmark of malignancy
Author:
- 10 April 2026
- journal article
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 119 (8) , 591-596
Abstract
Cancer progression is commonly interpreted through genetic mutation and clonal selection. While this framework explains many aspects of tumour initiation, it does not fully account for prolonged dormancy, late relapse, spatial heterogeneity, or metastasis occurring without new driver mutations. Increasing evidence indicates that these behaviours are governed by reversible regulatory processes operating downstream of DNA sequence. Here, we advance an RNA-centric framework in which transcriptional reinforcement and RNA fate control jointly shape tumour evolution across time and space. We focus on exon-mediated activation of transcription starts (EMATS), a mechanism whereby efficient exon recognition stabilises promoter-proximal RNA polymerase II, suppresses premature termination, and amplifies transcription from weak or context-dependent promoters without requiring promoter mutation, enhancer rewiring, or immediate protein output. The resulting transcripts are subsequently filtered through RNA fate checkpoints that determine nuclear retention, decay, or persistence, uncoupling transcriptional activity from translation. Within this model, non-coding and non-canonical RNAs function as spatiotemporal reporters of tumour state, encoding when and where transcriptional programmes are engaged. RNA persistence enables tumour cells to remain transcriptionally primed under hypoxia, therapeutic pressure, or immune surveillance, supporting dormancy and rapid reactivation. By reframing tumour evolution as RNA state regulation, this framework provides a mechanistic basis for plasticity, relapse, and therapy resistance, and highlights RNA states as clinically actionable biomarkers and vulnerabilities.Keywords
This publication has 34 references indexed in Scilit:
- Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targetsScience China Life Sciences, 2020
- Exon-Mediated Activation of Transcription StartsCell, 2019
- The Functional Impact of Alternative Splicing in CancerCell Reports, 2017
- SRSF1-Regulated Alternative Splicing in Breast CancerMolecular Cell, 2015
- Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanomaBritish Journal of Cancer, 2014
- How Slow RNA Polymerase II Elongation Favors Alternative Exon SkippingMolecular Cell, 2014
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The Spliceosome: Design Principles of a Dynamic RNP MachineCell, 2009
- Mechanical Devices of the Spliceosome: Motors, Clocks, Springs, and ThingsCell, 1998
- Initial splice-site recognition and pairing during pre-mRNA splicingCurrent Opinion in Genetics & Development, 1996